AstraZeneca, a pharmaceutical giant with a growing presence in Virginia’s life sciences industry, announced plans to build the largest drug-manufacturing facility in the entire world in Virginia. This will be the single largest investment in the history of the company.
The U.K. biopharmaceutical firm said that the new facility would be a cornerstone in its $50 billion U.S. growth plan by 2030. The site will produce treatments for cancer, respiratory illnesses, and rare diseases. It is expected to create hundreds highly-skilled jobs, use AI, automation and advanced data analytics, to optimize production.
Gov. Glenn Youngkin, AstraZeneca CEO Pascal Soriot, and White House National Economic Council director Kevin Hassett were present at the Washington, D.C. announcement. Glenn Youngkin said that the move is a milestone for Virginia’s economic development.
Youngkin thanked AstraZeneca’s decision to make Virginia the foundation for this investment. This project will be a benchmark for technological advances in pharmaceutical manufacturing. It will create hundreds of high-skilled jobs, and help strengthen the domestic supply chain .”
The company chose Virginia for its skilled workforce and commitment to innovation, as well as the research institutions.
AstraZeneca’s record-breaking wager on Virginia comes at an important economic juncture in the Commonwealth, which is struggling with job losses — especially in its large federal sectors.
Virginia’s unemployment rate climbed to 3.5% in June according to the U.S. Bureau of Labor Statistics. This marks six consecutive months of increasing rates. According to the U.S. Bureau of Labor Statistics, Virginia has experienced a loss of 11,100 federal jobs this year. This is primarily due to Northern Virginia federal workers and contractors.
The University of Virginia’s Weldon-Cooper Center predicts that total job lossesmay reach 32,000 before the end of the year, due to federal layoffs.
AstraZeneca’s new facility for manufacturing drug substances will produce key ingredients to treat oncology, cardio-renal and metabolic diseases, immunological and respiratory conditions, as well as other rare disorders.
According to CEO Soriot, the investment demonstrates the company’s global ambitions as well as its confidence in America’s future biopharmaceutical.
Soriot stated that “today’s announcement demonstrates our belief in America’s biopharmaceutical innovation and our commitment to millions of patients in America and around the world who need our medicine.” It will also support our ambitious goal to reach $80 Billion in revenue by the year 2030 .”
He said that the partnership with Virginia is a reflection of the state’s wish to create science-based jobs at high wages and to help bolster the U.S. medicine supply chain.
Virginians of all political stripes welcomed the announcement with enthusiasm.
Virginia Secretary of Commerce and Trade Juan Pablo Segura said the project was proof that Virginia has become a leading hub for life sciences.
AstraZeneca sells its medicines in more than 125 countries. The new Virginia facility is expected to become an important part of the global production network. The exact location or construction schedule of the new plant has not been disclosed by the company.
The announcement is made at a time when the U.S. has refocused on pharmaceutical manufacturing, especially after supply chain disruptions during pandemics. AstraZeneca’s decision places Virginia at the heart of this effort, which stakeholders hope will encourage other industry leaders follow suit.
AstraZeneca is increasingly focused on the U.S. Market, which will generate more than 40% the total revenue of the company in 2024.
Before Donald Trump’s return to office, the multinational pharmaceutical company had prioritized expansion in the United States. The market is the largest in the world, with a value of $635 billion.
The Trump administration is signaling a more aggressive approach to the manufacturing industry with its latest move.
The president floated the idea for new import tariffs to be placed on pharmaceuticals. He is also pressuring companies that they should produce more medicines in-house rather than relying solely on foreign facilities.
Although Trump’s efforts to reduce U.S. drug costs to levels that are comparable to those of other countries have largely avoided the previous trade disputes involving the pharmaceutical industry, he has renewed his call to do so.
